TIBS, along with its affiliates, has invested US$15 million in Axcynsis Therapeutics, a Singapore-based biotechnology company focusing on the development of innovative antibody drug conjugate therapeutics.

Target Information

Axcynsis Therapeutics, established in March 2022, is a biotechnology firm based in Singapore that specializes in the discovery and development of novel antibody drug conjugate (ADC) therapeutics. Led by CEO Dr. Zou Bin, the company boasts extensive expertise in drug discovery, operational management, and investment, marking him as a passionate entrepreneur with a proven track record, including the founding of two biotechnology startups. Prior to his role at Axcynsis, Dr. Zou served as CEO of TIBS, bringing valuable experience in the biotech sector.

ADC technology, the focus of Axcynsis, is made up of three crucial components: an antibody, a drug payload, and a linker. Variations in the design and arrangement of these components can lead to significantly different clinical outcomes. This area of research is rapidly expanding within cancer treatment and the market for ADCs is expected to surpass US$16 billion by 2026, highlighting its importance and potential for growth.

Industry Overview in Singapore

The biotechnology industry in Singapore has flourished due to the country’s strategic investments in research and development, as well as favorable government policies that support innovation. With a strong network of research institutions, academi